REGULATORY T CELL EPITOPES
The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprises a polypeptide comprising at least a portion of SEQ NOS: 1-124 (and/or fragments and variants thereof), and optionally 1 to 12 additional amino acids distributed in any ratio on the N-terminus and/or C-terminus of the polypeptide of SEQ ID NOS: 1-124, as well as methods of producing and using the same.
1 - 88 . (canceled)
89 . A polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 7 and SEQ ID NO: 14, and/or fragments and variants thereof, and optionally 1 to 12 additional amino acids distributed in any ratio on the N terminus and/or C-terminus of the polypeptide of SEQ ID NO: 7 or SEQ ID NO: 14.
90 . A nucleic acid encoding a polypeptide of claim 89 .
91 . A vector comprising the nucleic acid according to claim 89 .
93 . A cell comprising the vector according to claim 91 .
94 . A method of inducing regulatory T-cells to suppress immune response in a subject comprising administrating to the subject a therapeutically effective amount of a T-cell epitope composition, wherein the T-cell epitope composition comprises one or more isolated T-cell epitope polypeptides of claim 89 , wherein at least one isolated T-cell epitope polypeptide consists of the amino acid sequence of SEQ ID NO: 14.
95 . The method of claim 94 , wherein the T-cell epitope composition comprises two or more T-cell epitope polypeptides comprising of an amino acid sequence selected from the group consisting of SEQ ID NOS. 1-13 and 15-124.
96 . The method of claim 94 , wherein the T-cell epitope composition further comprises an effective amount of one or more antigens and/or allergens.
97 . The method of claim 94 , wherein the immune suppressive effect is mediated by natural regulatory T cells.
98 . The method of claim 94 , wherein the immune suppressive effect is mediated by adaptive regulatory T-cells
99 . The method of claim 94 , wherein the T-cell epitope composition suppresses an effector T-cell response.
100 . The method of claim 94 , wherein the T-cell epitope composition suppresses a helper T-cell response.
101 . The method of claim 94 , wherein the T-cell epitope composition suppresses a B-cell response.
102 . The method of claim 94 , wherein the T-cell epitope composition suppresses a cytokine secretion of effector T-cells.
103 . A composition comprising an effective amount of one or more isolated regulatory T cell epitopes and/or fragments and variants thereof comprising the polypeptide according to claim 89 and one or more immune stimulating T-cell epitope polypeptides, wherein said composition suppresses the immune response activated by said immune stimulating T-cell epitope polypeptide.
104 . The composition according to claim 103 , wherein said one or more immune stimulating T-cell epitope polypeptides is one or more therapeutic protein, treatment with a vaccine or treatment with at least one antigen.
105 . A pharmaceutical composition comprising one or more isolated regulatory T cell epitope (Tregitope) effective to suppress an immune response in a human, wherein at least one isolated regulatory T cell epitope peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7 or 14, and/or fragments and variants thereof, and optionally 1 to 12 additional amino acids distributed in any ratio on the N terminus and/or C-terminus of the polypeptide of SEQ ID NO: 7 or 14.
106 . The pharmaceutical composition according to claim 105 , wherein the at least one isolated regulatory T cell epitope peptide comprises SEQ ID NO: 14.
107 . The pharmaceutical composition of claim 105 further comprising a pharmaceutically acceptable carrier.